Palvella Therapeutics (PVLA)
NASDAQ:PVLA
Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$130.01
-$0.34(-2.31%)
At close: 4:00 PM EST
$130.01
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$20.20 - $151.18
Previous CloseN/A
Volume11.83K
Average Volume (3M)262.64K
Market Cap
$1.84B
Enterprise Value$1.39B
Total Cash (Recent Filing)$57.98M
Total Debt (Recent Filing)$633.00K
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding14,313,659
10 Day Avg. Volume230,794
30 Day Avg. Volume262,640
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-54.12
Forecast
1Y Price Target
$232.50Price Target Upside78.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-5.16
Revenue Forecast (FY)$26.67K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 SELVA results demonstrated strong and clinically meaningful improvements on key disease severity measures for microcystic lymphatic malformations, supporting the therapy's potential as an effective frontline treatment.
Commercial Potential And Platform ExpansionStrong physician receptivity in surveys, recent hires in market access and patient services, and plans to pursue additional mTOR-driven indications support differentiated commercial opportunity beyond a single product.
Regulatory PathwayBreakthrough Therapy designation and regulatory precedent for single-arm trials in similar orphan conditions increase the likelihood of an approvable regulatory path based on clinical endpoints rather than novel surrogate biomarkers.
Bears Say
Financial PressureOngoing net losses, significant cash burn and notable short interest create financing risk that could pressure operations and delay planned development or launch activities.
Patient Adherence RiskExpected plateau in improvement after several months combined with the need for daily topical application could hinder long-term patient adherence and limit real-world treatment durability.
Regulatory And Pediatric Access UncertaintyRegulators may require a placebo-controlled pivotal arm and initial approval could be limited to older children, which would complicate trial design and constrain early pediatric access.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $20.20 and its highest was $151.18 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $1.84B.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is May 14, 2026 which is in 14 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Mar 31, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.935 by -$0.145.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 14,313,659 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.935. Following the earnings report the stock price went up 12.642%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$232.50 (78.83% Upside)
$232.50 (78.83% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 193.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $850.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Earnings Call
Q4 2026
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$232.50
▲(78.83% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
1.92% Insiders
3.52% Mutual Funds
0.72% Other Institutional Investors
85.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---